Member Info for pjmcgra

I have now been invested for years, mainly at the top end range 0.74 -0.96 and even a trade at 1.12.
I love your optimism Stoney, thanks for the info .
Lets hope the BOD come back rejuvenated and get these SDC-1801 , SDC-1802 and TYKE 2 over the line.
It has been a while.
Merry Xmas all holders
PJ

With these positive results imminent, how long would it be to go into commercial ? Anyone with any info appreciated.
The units out on trial ( I believe six ) would they now be a sale surely.
This could be the start of something big, Riichard`s vlog with JW , very encouraging albeit couple of weeks ago.
GLAH and A Merry Xmas.
PJ

During this nasty exchange between people and open , are those amongst us interested in buying the 3p share offer, love to get a census .
PJ
GLAH

Have the GSPC no respect or integrity, there are not enough expletives the way we have been treated by them.
We had to go to arbitration and winning that argument, they still pull away, because It did not suit their agenda .
When are the OEX negotiators going step up and shout loud and get this through, for all our sakes.
GLAH.
PJ

Thanks for the update Adam, informative. Lets hope in your words GSPC days are numbered.
Regards
PJ

Hi all , please can someone one, more up to speed than myself, update me as to the latest in the Cambay ,
I thought after the arbitration it was ready steady go, reading the latest it appears the GSPC are still lingering ,
delaying yet further, this after the judgement was in put place ( in our favour ) , my question is, why can we not get on and drill on the site?
I would like to be re- assured.
GLAH
PJ

Today, saw some BIG buys and NO sells , news is coming in a couple of weeks with, we hope FDA approval .
As a small Investor, I will be topping tomorrow , THIS A VERY GOOD TECH at low risk and I believe in Richard H to deliver what he believes , looking forward to happy days.
GLAH
PJ

Thanks for that Aim .
PJ

Good news, the Company has delivered and installed its latest research unit order for a 9820 Xenon Polariser system from the University of British Columbia in Canada This will act as a support for their research .Following delivery of this order, the total number of the Company's polarisers that are either installed or on order is 25.
I cannot rightly remember how many machines Richard said, would have to be in circulation before becoming viable, it wasn't a lot based on costings .Following the FDA IN Q2 next year and the right marketing this could be massive.
Consider it is only in parts of USA and in Canada at present, forward onto South America, China, India, Europe , Asia ,Africa and Australia.
I`m thinking, in the UK alone , one or two in every county , that's a lot !
There is a surprise though , the SP has dropped ? I`m topping up anyway .
GLAH
PJ

Do we know the cost of each unit
 
The UBC polariser is initially being installed at BC Children's Hospital (http://www.bcchildrens.ca/) while construction proceeds on its ultimate site at UBC. BC Children's is a major paediatric research and teaching hospital. This new unit will support their paediatric pulmonary disease research programme using hyperpolarised gas imaging. Their order was enabled by a grant from the Canada Foundation for Innovation ("CFI") www.innovation.ca/about. Following delivery of this order, the total number of the Company's polarisers that are either installed or on order is 25.
 
Richard Hullihen, CEO of Polarean, said: "We have now delivered and installed our latest polariser, which is a platform for the researchers at BC Children's Hospital, expanding our paediatric research cluster which includes Cincinnati Children's Hospital Medical Center and Toronto SickKids Hospital. We look forward to enabling their new discoveries in these critical projects and we welcome UBC to the group."

The Cambay
The Cooper Basin and
the u k project. what potential .
glah
PJ

Patience is a requirement on this site, absorb the news of the trials ,
Medical imaging technology company Polarean Imaging, which has a proprietary magnetic resonance imaging (MRI) drug-device combination, announced on Thursday that the enrolment for its phase 3 non-inferiority clinical trials was now complete for both the lung transplant pathway and the lung resection pathway.
We are up against 40 year old tech ,it was inevitable new tech would come along and here it is . Can you imagine how helpful this will be in such conditions of cystic fibrosis ,asthma and others , what a revelation.
GLAH
Regards
PJ

Any day now , this share will move rapid , on the impending P3 clinical results.
I will be having a nibble on Monday at 19p
GLAH

HIGHLIGHTS

CAMBAY FIELD, ONSHORE GUJARAT, INDIA
I have been following this board for a couple of years with a good bit invested , but , like many , feel frustrated as to GSPC attitude and reluctance to deal with OEX, is it they want the CAMBAY for themselves , having no funding they have no intention of a deal as a previous post stated they missed the June payment 2019.
Only hope arbitration calls in favour of OEX .
Lets be honest I do not want to rely on the COOPER BASIN and the UK projects , the CAMBAY has plenty of potential .
GLAH

VOX market information , an overview as to POLX position.

About Polarean (www.polarean.com)
 The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue generating, medical drug-device combination companies operating in the high resolution functional magnetic resonance imaging market.
  
The Group develops equipment that enables existing MRI systems to achieve an improved level of pulmonary function imaging and specialises in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualise ventilation and gas exchange regionally in the smallest airways of the lungs, the tissue barrier between the lung and the bloodstream and in the pulmonary vasculature. Xenon gas exhibits solubility and signal properties that enable it to be imaged within other tissues and organs.
 
The Group operates in an area of significant unmet medical need and the Group's technology provides a novel diagnostic approach, offering a non-invasive and radiation-free functional imaging platform which is more accurate than current methods. The annual burden of pulmonary disease in the US is estimated to be over US$150 billion.

Polarean Imaging PLC - Phase III Clinical Trials update
First patient enrolment at University of Cincinnati .
 
Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces that the first patient has been enrolled in its third trial site at the University of Cincinnati ("UC").
 
As announced on 11 June 2019, the Company added a third trial site, in addition to Duke University and the University of Virginia, to improve enrolment rates for its Phase III Clinical Trials (the "Clinical Trials"). The Clinical Trials aim to demonstrate non-inferiority of the Company's drug-device combination, which uses hyperpolarised 129-Xenon gas MRI, against an approved comparator for the evaluation of pulmonary ventilation.
 
Enrolment for the Clinical Trials has now passed 98% in the lung transplant pathway and 75% in the lung lobe resection pathway, with a total of 80 patients targeted for enrolment. The Company remains on target to complete enrolment for the Clinical Trials before the end of Q3 2019.
 
Richard Hullihen, CEO of Polarean, said: "The first patient enrolment at our additional trial site at UC provides reinforcement that we will deliver on our commitment to a timely completion of enrolment for the Clinical Trials. We remain focused on the completion of our New Drug Application and submission to the US Food and Drug Administration following readout of the Clinical Trials. We are funded to complete this and undertake post submission launch preparation and planning. I look forward to providing our shareholders with further updates regarding the Clinical Trials as they near completion."

GLAH
 

IMHO , Vox market interview with CEO Richard Hullihan very positive, also an independent interview stating this share as a no brainer, check it out . clinical results end of September ,positive, and finally FDA license in Q1 2020, hold onto your hats.
I will be topping up at 20p.
GLAH.